Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.12 EUR
Change Today +0.007 / 0.14%
Volume 6.3K
As of 11:18 AM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

vita 34 ag (V3V) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - €7.38
52 Week Low
10/13/14 - €3.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VITA 34 AG (V3V)

Related News

No related news articles were found.

vita 34 ag (V3V) Related Businessweek News

No Related Businessweek News Found

vita 34 ag (V3V) Details

Vita 34 AG operates as an umbilical cord blood bank in Germany, Austria, Switzerland, and Spain. The company operates in two segments, Stem Cell Storage and Biotechnology. The Stem Cell Storage segment collects, processes, and stores stem cells from umbilical cord blood and umbilical cord tissue, as well as develops cell therapy procedures. The Biotechnology segment develops biological processes for cell and tissue culture, as well as employs them in the optimization and multiplication of cells and plants. The company also offers VitaPlusDonation, a program that provides parents an alternative to the pure autologous storage or allogenic donation of umbilical cord blood; and Sibling Initiative program, which allows the free of charge storage of stem cells from the umbilical cord of a child whose brother or sister is seriously ill. It also provides Prevention Screening service, which enables the detection of genetically related health risks and predispositions; and mobile stem cell service that facilitates the treatment with stem cells from umbilical cord blood in various hospitals. The company was founded in 1997 and is headquartered in Leipzig, Germany.

110 Employees
Last Reported Date: 03/26/15
Founded in 1997

vita 34 ag (V3V) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €296.0K
Compensation as of Fiscal Year 2014.

vita 34 ag (V3V) Key Developments

VITA 34 AG Announces Executive Changes Effective from October 1, 2015

Vita 34 AG announced that as of October 1, 2015 the new CFO at the company will be Falk Neukirch. He will lead the company together with the chairman of the management board, Dr. Andr Gerth. Falk Neukirch will be taking over the helm from Jrg Ulbrich, who was a member of the Management Board for seven years. This change in the finance area took place by mutual agreement. The new Chief Financial Officer is assuming the role with the goal of mastering the necessary strategic market challenges in the Management Board team in order to develop Vita 34 AG into a globally leading specialist for the storage and application of stem cells, while maintaining profitable growth.

Vita 34 AG Approves First Dividend Payment; Announces Appointments of Supervisory Board

Annual General Meeting of Vita 34 AG approved the proposal made by the management and supervisory boards to pay a dividend in the amount of EUR 0.15 per share with a large majority due to the greatly improved income situation. This is equivalent to a dividend yield of some 2.5%. In addition, within the course of changing the by-laws the number of supervisory board members was increased from three to six. Artur Isaev, Heinrich Sundermeyer and Ms. Gerrit Witscha were elected as new supervisory board members. Dr. med. Mariola Shngen was elected as an alternate for the supervisory board. In the subsequent meeting of the supervisory board Dr. Hans-Georg Giering was confirmed as chairman and Alexander Starke elected as deputy chairman of the supervisory board, after Dr. Holger Fdisch made this function available for personal reasons.

VITA 34 AG Announces Earnings Results for the Six Months Ended June 30, 2015

VITA 34 AG announced earnings results for the six months ended June 30, 2015. Total operating revenue increased by 6% to EUR 7.1 million following EUR 6.7 million in the prior year's reference period. Revenues generated by Vita 34 rose by 5% to EUR 6.4 million (first half-year 2014: EUR 6.1 million), of which EUR 3.3 million were in second quarter of 2015 (second quarter of 2014: EUR 2.9 million). Earnings before interest, taxes, depreciation and amortization (EBITDA) increased above average by 38% to EUR 1.1 million in the first six months, following EUR 0.8 million in the prior year's period. Measured on revenues Vita 34 achieved a strong EBITDA margin of 17.4% (first half-year 2014: 13.4%). The period result improved by 300% to EUR 0.4 million following EUR 0.1 million in the 2014 reference period. This corresponds to earnings per share of EUR 0.13 (first half-year 2014: EUR 0.05) which represents a 160% increase.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
V3V:GR €5.12 EUR +0.007

V3V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for V3V.
View Industry Companies

Industry Analysis


Industry Average

Valuation V3V Industry Range
Price/Earnings 12.1x
Price/Sales 1.2x
Price/Book 0.8x
Price/Cash Flow 12.1x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VITA 34 AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at